In particular, given that synergistic action of Sirpα/CD47 blockade and ICBs has been reported in other tumor types [200], neutralization of Sirpα represents an attractive approach to increase the responsiveness of CRC patients to ICB. This evidence concerns the gene CD47 and neoplasm.